News & Updates

Individuals who have recently received a diagnosis of gout face an increased risk of cardiovascular events within 30 days of the index diagnosis, according to a study.

Combining verinurad with allopurinol does not appear to boost oxygen uptake or improve symptoms in heart failure with preserved ejection fraction (HFpEF), despite yielding significant reductions in serum uric acid (SUA) levels, according to a phase II study.

Women with vasculitis who get pregnant can deliver live births at term, although flares or hospitalization due to vasculitis may occur during pregnancy, according to a study.

Rheumatology ambulatory care must adequately respond to the need of patients with inflammatory arthritis (IA) to reduce their visits to the emergency department (ED), suggests a study.

New drug applications approved by US FDA as of 1-15 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 16-30 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

EP-104IAR, a diffusion-based long-acting formulation of fluticasone propionate for intra-articular injection, appears to produce meaningful reductions in knee osteoarthritis (OA) pain that last up to 14 weeks, according to data from a phase II SPRINGBOARD study.

In the treatment of patients with active psoriatic arthritis (PsA), intravenous secukinumab appears to yield rapid and sustained improvements in clinical measures, with a safety profile consistent with that of the subcutaneous formulation, according to the phase III INVIGORATE-2 study.